Table 2.
no SIRS vs SIRS patients characteristics
| Data | No SIRS group (n = 16) |
SIRS group (n = 16) |
P value |
|---|---|---|---|
| Male/female | 12/4 | 13/3 | 0.986 |
| Age (years) | 74 (69-77) | 69 (60-79) | 0.46 |
| ASA physical status (III/IV) | 14/2 | 8/8 | 0.057 |
| EuroSCORE | 9 ± 3 | 9 ± 4 | 0.963 |
| LVEF <40% | 7 (44%) | 5 (31%) | 0.693 |
| Perioperative beta blockers | 4 (25%) | 3 (27%) | 0.74 |
| Baseline biologic measurements | |||
| - WBC (G/L) | 7.6 ± 2.5 | 7.6 ± 2.1 | 0.817 |
| - CRP (mg/L) | 1.8 (1.1-5.7) | 6.7 (2.2-14.3) | 0.016 |
| - PCT (ng/L) | 0.07 (0.06-0.1) | 0.09 (0.09-0.20) | 0.052 |
| - BPW (%T/s) | 0.02 ± 0.02 | 0.03 ± 0.02 | 0.423 |
| SAPS II score | 29 (23-30) | 32 (23-43) | 0.221 |
| Surgical procedure | |||
| - Valvular surgery | 5 (30%) | 10 (62%) | _ |
| - Combined surgery | 2 (13%) | 3 (19%) | |
| - Ascending aortia surgery | 7 (44%) | 3 (19%) | |
| - CABG | 2 (13%) | 0 | |
| CPB duration (min) | 106 (81-116) | 120 (92-146) | 0.09 |
| Aortic cross clamping time (min) | 75 ± 25 | 88 ± 31 | 0.187 |
| Length of stay in the ICU (days) | 2 (2-4) | 5 (4-15) | 0.006 |
| Post operative complication | |||
| - Reoperation | 0 | 4 (25%) | 0.11 |
| - Hemorrhage | 2 (13%) | 5 (31%) | 0.42 |
| - Tamponade | 0 | 2 (13%) | 0.44 |
| - Inotropic support | 1 (6%) | 5 (31%) | 0.17 |
| - Myocardial infarction | 0 | 1 (6%) | 0.97 |
| - AKI requiring RRT | 0 | 3 (19%) | 0.22 |
| Death (n) | 0 | 4 (25%) | 0.11 |
Data are expressed as mean ± standard deviation, median (interquartile range), or number (percentage).
AKI = acute kidney injury; ASA = American Society of Anesthesiology; BPW = biphasic waveform; CABG = coronary artery bypass grafting; CPB = cardiopulmonary bypass; CRP = C-reactive protein; EuroSCORE = European system for cardiac operative risk evaluation; ICU = intensive care unit; LVEF = left ventricular ejection fraction; PCT = procalcitonin; RRT = renal replacement therapy; SAPS II = simplified acute physiology score; SIRS = systemic inflammatory response syndrome; WBC = white blood cell.